Tulane University
A translational research and external engagement unit within Tulane School of Medicine that connects industry, investors, and collaborators to university expertise, research tools, preclinical models, diagnostics, and commercialization support. Services include sponsored research, co-development, licensing, matchmaking to key opinion leaders, and facilitation of startup partnerships.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Apparatus, systems and methods for in vitro screening of complex biological fluids
US-12566124-B2
View Details
Apparatus, systems and methods for in vitro screening of complex biological fluids
US-12566124-B2
View DetailsProducts
Lipid nanoparticle and outer-membrane-vesicle adjuvant systems
Adjuvant platforms demonstrated to stimulate humoral and cellular immune responses, including CD8+ T-cell induction and mucosal immunity with intranasal delivery.
Synthetic antimicrobial peptide therapeutics
Synthetically evolved peptides that rapidly lyse bacterial membranes, active against drug-resistant ESKAPE pathogens and biofilms, with formulations demonstrating extended stability.
Patient-derived xenograft (PDX) cohorts and organoid libraries
Collections of PDX models, organoids and cell lines (e.g., triple-negative breast cancer) for target identification and drug efficacy testing.
High-sensitivity molecular diagnostics and assay workflows
Assay development and validation for low-abundance nucleic acid detection, multiplex pathogen testing, and on-chip immune assays.
Gene therapy research tools and delivery approaches
Preclinical gene-delivery constructs and airway-delivery methods tested in models of lung fibrosis and metabolic disease.
Lipid nanoparticle and outer-membrane-vesicle adjuvant systems
Adjuvant platforms demonstrated to stimulate humoral and cellular immune responses, including CD8+ T-cell induction and mucosal immunity with intranasal delivery.
Synthetic antimicrobial peptide therapeutics
Synthetically evolved peptides that rapidly lyse bacterial membranes, active against drug-resistant ESKAPE pathogens and biofilms, with formulations demonstrating extended stability.
Patient-derived xenograft (PDX) cohorts and organoid libraries
Collections of PDX models, organoids and cell lines (e.g., triple-negative breast cancer) for target identification and drug efficacy testing.
High-sensitivity molecular diagnostics and assay workflows
Assay development and validation for low-abundance nucleic acid detection, multiplex pathogen testing, and on-chip immune assays.
Gene therapy research tools and delivery approaches
Preclinical gene-delivery constructs and airway-delivery methods tested in models of lung fibrosis and metabolic disease.
Services
Negotiation and management support for sponsored research agreements, co-development projects, and licensing of university technologies.
Connecting companies to domain experts across clinical and basic science areas for advisory roles, media appearances, or scientific guidance.
Provision of validated preclinical models, diagnostic assays, and research tools for external collaborations and licensing.
Curation and dissemination of faculty publications and research highlights to support partner evaluation.
Negotiation and management support for sponsored research agreements, co-development projects, and licensing of university technologies.
Connecting companies to domain experts across clinical and basic science areas for advisory roles, media appearances, or scientific guidance.
Provision of validated preclinical models, diagnostic assays, and research tools for external collaborations and licensing.
Curation and dissemination of faculty publications and research highlights to support partner evaluation.
Expertise Areas
- Vaccine development and adjuvant research
- Infectious disease diagnostics
- Preclinical model development (PDX, organoids, NHP models)
- Antimicrobial peptide therapeutics
Key Technologies
- CRISPR-based molecular diagnostics
- Lipid nanoparticle and outer-membrane-vesicle adjuvant systems
- Patient-derived xenografts (PDX) and organoids
- Synthetic antimicrobial peptides
News & Updates
Publication describing adjuvant research that drives mucosal and systemic B cell responses and CD8+ T-cell induction in preclinical models.
Publication describing synthetic evolution and optimization of antimicrobial peptides active against drug-resistant bacteria and biofilms.
Reports of 1,000+ business development interactions per year via the engagement unit.
$60M+ in federal awards reported for Tulane University School of Medicine (FY2025).
280+ original research publications in FY22 and ~620 biomedical-focused faculty reported on the site.
$205M NSF research expenditures reported (FY21).
Publication describing adjuvant research that drives mucosal and systemic B cell responses and CD8+ T-cell induction in preclinical models.
Publication describing synthetic evolution and optimization of antimicrobial peptides active against drug-resistant bacteria and biofilms.
Reports of 1,000+ business development interactions per year via the engagement unit.
$60M+ in federal awards reported for Tulane University School of Medicine (FY2025).
280+ original research publications in FY22 and ~620 biomedical-focused faculty reported on the site.
$205M NSF research expenditures reported (FY21).